Clinical trials: Leishmaniasis, Cutaneous
Leishmaniasis, Cutaneous
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
This clinical trial aims to evaluate the effectiveness of combining the standard treatment for complicated cutaneous leishmaniasis (CL), sodium stibogluconate (SSG), with either topical fusidic acid 2% cream or a vehicle cream…
- Trial name
- AIM-CL (NCT06695143)
- Testing
- Fusidic Acid, Vehicle cream
- Where
- 2 sites in Ethiopia
- Volunteers
- 180 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniases
Outcomes of Complicated CL in Ethiopia Treated With Miltefosine
Cutaneous Leishmaniasis in Ethiopia causes severe dermatological mutilations. Forms that require systemic treatment are cLCL, MCL, and DCL. National guidelines recommend equally all drugs that are also used for VL treatment.
- Trial name
- NCT04004754
- Testing
- Miltefosine (administration is not part of study procedures)
- Where
- 2 sites in Ethiopia
- Volunteers
- 94 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Skin Diseases, Parasitic
Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia
The purpose of the study is to evaluate the sensitivity and specificity of CL Detect, in subjects with suspected CL in Tunisia.
- Trial name
- CL Detect™ (NCT01769612)
- Testing
- No Intervention
- Where
- 2 sites in Tunisia
- Volunteers
- 168 people
- Sponsor
- U.S. Army Medical Research and Development Command
Mucocutaneous Leishmaniasis
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
This study is a Phase 4, open-label, single group study in which at least 40 adult patients undergoing miltefosine treatment for mucocutaneous leishmaniasis (CL and ML) will be assessed by 12-lead ECG for prolongation of the…
- Trial name
- NCT02429518
- Testing
- Miltefosine
- Where
- Bolivia
- Volunteers
- 42 people
- Sponsor
- Knight Therapeutics (USA) Inc
Leishmaniasis, Cutaneous
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 15 different species of the protozoan parasite Leishmania.
- Trial name
- Curaleish (NCT04072874)
- Testing
- Experimental topical (Curaleish Topical)
- Where
- Colombia
- Sponsor
- Universidad de Antioquia
Leishmaniasis, Cutaneous Leishmaniasis
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Intralesional injection of antimony has been used for L major from Iran with a modest cure rate [56%: Asilian 2004]. However, this therapeutic approach has been used for L braziliensis from Brazil, with an attractive cure rate…
- Trial name
- NCT01300975
- Testing
- pentavalent antimony, cryotherapy
- Where
- 2 sites in Bolivia
- Volunteers
- 90 people
- Sponsor
- Fundacion Nacional de Dermatologia
Leishmaniasis; American, Cutaneous, Drug Side Effect
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
- Trial name
- NCT03084952
- Testing
- 18-Methoxycoronaridine, Glucantime
- Volunteers
- 52 people
- Sponsor
- Infan Industria Quimica Farmaceutica Nacional
Cutaneous Leishmaniasis
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
"Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis " has begun in October 2008 at the Laboratory of…
- Trial name
- NCT01301924
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Oswaldo Cruz Foundation
Cutaneous Leishmaniasis
Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis.
- Trial name
- NCT06797544
- Testing
- Levofloxacin 0.5%
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Hayder Adnan Fawzi
Cutaneous Leishmaniasis
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
The purpose of this study is to determine whether low-dose pentavalent antimony is equally effective when compared to the standard-dose regimen in patients with cutaneous leishmaniasis.
- Trial name
- Lowdosesb (NCT00317980)
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University of Brasilia
Leishmaniasis, Cutaneous, Vector Borne Diseases
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
The aim of this study is to determine the efficacy of Mosquito Shield (spatial repellent) in reducing cutaneous leishmaniasis case incidence among internally displaced persons and sandfly density in temporary shelters and camp…
- Trial name
- NCT06917040
- Testing
- Spatial repellant emanator
- Where
- Syria
- Volunteers
- 18,404 people, healthy volunteers welcome
- Sponsor
- The Mentor Initiative
Cutaneous Leishmaniasis, American
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
Cure rate for L braziliensis bolivian CL has been 70%-80% for standard systemic and local monotherapies. It would benefit patients if cure rates could be consistently >90%, so testing a combination of two treatments is proposed.
- Trial name
- NCT03829917
- Testing
- Miltefosine and Paromomycin, miltefosine, paromomycin
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Healthy
Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin
Development of a safe and effective vaccine against leishmaniasis started more than 10 years ago under WHO/TDR supervision. An autoclaved L. major vaccine (ALM) mixed with BCG has been tested in human in Iran, Pakistan and Sudan.
- Trial name
- NCT00429715
- Testing
- Alum-ALM + BCG
- Where
- Iran
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Post Kala Azar Dermal Leishmaniasis
Ivermectin Repurposed for the Treatment of PKDL
Background (brief): 1. Burden: Post-Kala-Azar Dermal Leishmaniasis (PKDL) commonly follows visceral leishmaniasis (VL) caused by Leishmania donovani.
- Trial name
- NCT07286604
- Testing
- Ivermectin 6 MG Oral Tablet (2 tablets)
- Where
- Bangladesh
- Volunteers
- 10 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cutaneous Leishmaniasis
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin.
- Trial name
- NCT02281669
- Testing
- Pentostam
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Leishmaniasis, Cutaneous
Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
Background: Cutaneous Leishmaniasis is a worldwide disease, endemic in over 88 countries, that has shown an increasing incidence over the last many decades.
- Trial name
- NCT00480883
- Testing
- meglumine antimoniate, allopurinol, meglumine antimoniate
- Where
- Pakistan
- Volunteers
- 400 people
- Sponsor
- Combined Military Hospital, Pakistan
Cutaneous Leishmaniasis
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
Cutaneous leishmaniasis is a parasitic skin lesion caused by different species of Leishmania and transmitted by the bite of infected sand flies.
- Trial name
- NCT00351520
- Testing
- Miltefose
- Where
- Iran
- Volunteers
- 148 people
- Sponsor
- Tehran University of Medical Sciences
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Post Kala Azar Dermal Leishmaniasis
Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard…
- Trial name
- NCT00982774
- Testing
- LEISH-F2 + MPL-SE vaccine
- Where
- Sudan
- Volunteers
- 42 people
- Sponsor
- Access to Advanced Health Institute (AAHI)